340B was created to help serve patients with limited options, but today it rewards scale and billing volume. Congress and federal regulators must realign the provision with its original purpose.

The HHS wants to move oversight of 340B from the Health Resources and Services Administration to the CMS, a move that could prove negative for the the two-thirds of U.S. hospitals that rely on ...

The 340B drug pricing program, originally intended to help low-income and uninsured patients, has been exploited by special interests for profit, resulting in higher drug prices, taxes, and ...

340B was created to help serve patients with limited options, but today it rewards scale and billing volume. Congress and federal regulators must realign the provision with its original purpose.

Because 340B drugs are carved-out in these six states, covered entities are denied the 340B discount for Medicaid patients and must precisely invoice which drugs are resold to Medicaid patients.

However, the system has been misused; 340B has morphed into a way for large tax-exempt hospitals and for-profit chain pharmacies to markup medicine prices and boost their profits.

Apexus also holds “340B University” events to help providers and others in the health care industry understand the program, and it fields questions through a national call center.

Today, the 340B program is rife with fraud and abuse. It has morphed into a significant profit driver for large retail pharmacies, pharmacy benefit managers and hospitals in California.